Active Ingredient(s): Ozanimod Hydrochloride
FDA Approved: * March 25, 2020
Pharm Company: * CELGENE INTL
Category: Multiple Sclerosis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zeposia Overview

Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis (RMS) and ulcerative colitis.[2][3][4][5] It acts as a sphingosine-1-phosphate (S1P) receptor agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.[4] The most common adverse reactions are upper respiratory infection, hepatic t...

Read more Zeposia Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ozanimod

Recent Zeposia Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ozanimod Hydrochloride
  • Capsule: 0.23mg, 0.46mg, 0.92mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Zeposia: (1 result)

Sorted by National Drug Code
  • 59572-820 Zeposia .92 mg Oral Capsule by Celgene Corporation

Other drugs which contain Ozanimod Hydrochloride or a similar ingredient: (1 result)